Results 11 to 20 of about 1,943,371 (81)

Flood Analysis in Lower Filyos Basin Using HEC-RAS and HEC-HMS Software

Sustainability
Flood events have become more frequent as a result of seasonal changes, global warming, and changes in sea level. In terms of basin management, it is necessary to know the hydrodynamics of the basin in order to produce faster solutions in emergency ...
Berna Aksoy
semanticscholar   +2 more sources

Comparison of the power of lognormality tests with different right-tail alternative distributions.

, 2013
In flood frequency analysis (FFA), the adequate choice of distribution to fit data is a major problem. The three-parameter lognormal (LN3) distribution has an intermediate tail behavior between the distributions of the Class C (regularly varying ...
Barbara Martel, S. E. Adlouni, B. Bobée
semanticscholar   +2 more sources

Climatic impact on Rainfall Analysis in Al-Madinah Munawwara Region

IOP Conference Series: Earth and Environment, 2022
Long-term changes in temperature and weather patterns are referred to as climate change. Climate change and rainfall distribution are inextricably linked to arid and semi-arid regions. Saudi Arabia is entirely located in arid and semi-arid areas, and the
A. Aldrees
semanticscholar   +1 more source

A Combination between Synthetic Unit Hydrograph (SCS) and Rational Method in a similar Conditions Water Shed

Asian Journal of Engineering and Technology, 2021
Studying watershed characteristics and choosing the most applicable methods to determine the amount of access rainfall that ran off is very important in many engineering applications, especially hydrology applications.
M. Fathi, Neveen B. Abelmageed, M. Hassan   +2 more
semanticscholar   +1 more source

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

New England Journal of Medicine, 2022
BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard   +28 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, F. Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, C. Leath III, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al Baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages.
J. Llovet, Masatoshi Kudo, P. Merle, Tim Meyer, Shukui Qin, M. Ikeda, R. Xu, J. Edeline, B. Ryoo, Z. Ren, G. Masi, M. Kwiatkowski, H. Lim, Jeehyoung Kim, V. Breder, H. Kumada, A. Cheng, Peter R. Galle, S. Kaneko, Anran Wang, K. Mody, C. Dutcus, L. Dubrovsky, A. Siegel, R. Finn   +24 more
semanticscholar   +1 more source

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

New England Journal of Medicine, 2023
BACKGROUND No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.
M. S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi, M. Burotto, M. Schenker, J.P. Sade, A. Bamias, Philippe Beuzeboc, J. Bedke, Jan Oldenburg, G. Chatta, Y. Ürün, Dingwei Ye, Zhisong He, B. P. Valderrama, Ja Hyeon Ku, Y. Tomita, J. Filian, Lily Wang, D. Purcea, M. Patel, F. Nasroulah, M. Galsky   +23 more
semanticscholar   +1 more source

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

NEJM Evidence, 2022
Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional ...
G. Abou-Alfa, G. Lau, M. Kudo, S. Chan, R. Kelley, J. Furuse, W. Sukeepaisarnjaroen, Yoon-Koo Kang, T. Van Dao, E. D. De Toni, L. Rimassa, V. Breder, Alexander Vasilyev, A. Heurgué, V. Tam, K. Mody, S. Thungappa, Y. Ostapenko, T. Yau, S. Azevedo, M. Varela, A. Cheng, S. Qin, P. Galle, Sajid Ali, M. Marcovitz, M. Makowsky, P. He, J. Kurland, A. Negro, B. Sangro   +30 more
semanticscholar   +1 more source

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

New England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn, S. Qin, M. Ikeda, P. Galle, M. Ducreux, Tae-You Kim, M. Kudo, V. Breder, P. Merle, A. Kaseb, Daneng Li, W. Verret, Derek-Zhen Xu, Sairy G. Hernandez, Juan Liu, Chen Huang, S. Mulla, Yulei N. Wang, Ho Yeong Lim, A. Zhu, A. Cheng   +20 more
semanticscholar   +1 more source